___

Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008; 8:345-352.

Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 2016; 1263-1277.

Gahr M, Freudenmann RW, Hiemke C, Kolle MA, SchonfeldtLecuona C. Pregabalin abuse and dependence in Germany: Results from a database query. Eur J Clin Pharmacol 2013; 69:1335-1342.

Schifano F. Misuse and abuse of pregabalin and gabapentin: Cause for concern? CNS Drugs 2014; 28:491-496.

Smith R V., Havens JR, Walsh SL. Gabapentin misuse, abuse, and diversion: A systematic review. Addiction 2016; 111:1160-1174.

Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA 2018; 320:2149-2151.

Titck - Turkish Pharmaceutical and Medical Device Board. Narcotics and psychotropic substances. https://www.titck.gov. tr/faaliyetalanlari/ilac/uyusturucu-ve-psikotrop-maddeler. Accessed May 25, 2019. (Turkish)

Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6:108-113.

Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, Meltzer LT, Schwarz JB, Taylor CP, Thorpe AJ, Vartanian MG, Wise LD, Zhi-Su T, Weber ML, Wustrow DJ. Structureactivity relationships of pregabalin and analogues that target the α2-δ protein. J Med Chem 2005; 48:2294-2307.

Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49:661- 669.

Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28:75-82.

Bonnet U, Richter EL, Isbruch K, Scherbaum N. On the addictive power of gabapentinoids: A mini-review. Psychiatr Danub 2018; 30:142-149.

Martinotti G, Lupi M, Sarchione F, Santacroce R, Salone A, Berardis D, Serroni N, Cavuto M, Signorelli M, Aguglia E, Valchera A, Iasevoli F, Di Giannantonio M. The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview. Curr Pharm Des 2013; 19:6367-6374.

Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73:137-150.

Manville RW, Abbott GW. Gabapentin is a potent activator of KCNQ3 and KCNQ5 potassium channels. Mol Pharmacol 2018; 94:1155-1163.

Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs 2017; 77:403-426.

Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs 2016; 30:9-25.

Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farre M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, Van Der Kreeft P, Scherbaum N. Is there a recreational misuse potential for pregabalin? analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011; 80:118-122.

Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs 2012; 21:1243-1245.

Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs 2012; 21:1019-1029.

Forg A, Hein J, Volkmar K, Winter M, Richter C, Heinz A, Muller CA. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol 2012; 47:149-155.

Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, Mazza M, Romanelli R, Moroni N, De Filippis R, Di Giannantonio M, Pozzi G, Bria P, Janiri L. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2010; 24:1367-1374.

Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs 2018; 27:113- 124.

Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction 2019;add.14655.

Howland RH. Gabapentin: can it be misused? J Psychosoc Nurs Ment Health Serv 2014; 52:12-15.

Spigset O, Westin AA. Detection times of pregabalin in urine after illicit use: When should a positive specimen be considered a new intake? Ther Drug Monit 2013; 35:137-140.

Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol 2014; 78:190-191.

Nahar LK, Murphy KG, Paterson S. Misuse and Mortality Related to Gabapentin and Pregabalin are Being Under-Estimated: A Two-Year Post-Mortem Population Study. J Anal Toxicol 2019; bkz036

Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, Hickman M, Henderson G. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction 2017; 112:1580-1589.

Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 2013; 69:2021-2025.

Spence D. Bad medicine: gabapentin and pregabalin. BMJ 2013; 347:f6747.

Markowitz JS, Finkenbine R, Myrick H, King L, Carson WH. Gabapentin abuse in a cocaine user: implications for treatment? J Clin Psychopharmacol 1997; 17:423-424.

Khalid Z, Hennen M-A, Aldana-Bernier L. Gabapentin abuse by nasal insufflation. J Clin Psychopharmacol 2019; 39:89-91.

Victorri-Vigneau C, Guerlais M, Jolliet P. Abuse, dependency and withdrawal with gabapentin: a first case report. Pharmacopsychiatry 2007; 40:43-44.

Kruszewski SP, Paczynski RP, Kahn DA. Gabapentin-induced delirium and dependence. J Psychiatr Pract 2009; 15:314-319.

Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. J Clin Psychiatry 2007; 68:483-484.

Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf 2015; 10:184-186.

Ashwini S, Amit D, Ivan N, Alka P. Pregabalin dependence with pregabalin induced intentional self-harm behavior: A case report. Indian J Psychiatry 2015; 57:110-111.

Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010; 167:869.

Aldemir E, Altintoprak AE, Coskunol H. Pregabalin dependence: A case report. Turk Psikiyatr Derg 2015; 26:217-220. (Turkish)

Nordgaard J, Jurgens G. Pregabalin can cause addiction and withdrawal symptoms. Ugeskr Laeger 2015; 177:38-39. (Danish)

Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report. Psychiatry and Clinical Psychopharmacology 2011; 21:64-66.

Koroglu G. Pregabalin addiction in a case with synthetic cannabinoid use. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2017; 30:62-65.

Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol 2019; 85:1260-1269.

Iacobucci G. UK government to reclassify pregabalin and gabapentin after rise in deaths. BMJ 2017; 358:j4441.

Badgaiyan R. A Novel Perspective on Dopaminergic Processing of Human Addiction. J Alcohol Drug Depend 2013; 1:e101.

McAuley DF. How does pregabalin compare to gabapentin in the treatment of neuropathic pain? https://www.globalrph.com/old/ pregabalin.htm. Accessed May 29, 2019.

Clinical Guidelines on Drug Misuse and Dependence, Update 2017 Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London, 2017 https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/673978/clinical_ guidelines_2017.pdf. Accessed May 29, 2019.

Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J. Substance misuse of gabapentin. Br J Gen Pract 2012; 62:406-407.

Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol 2012; 32:839-840.

Naveed S, Faquih AE, Chaudhary AMD. Pregabalin-associated discontinuation symptoms: a case report. Cureus 2018; 10:e3425.

Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017; 27:1185-1215.

Barrett J, Kittler L, Singarajah C. Acute pregabalin withdrawal: a case report and review of the literature. Southwest J Pulm Crit Care 2015; 10:306-310.

Gahr M, Franke B, Freudenmann RW, Kolle MA, SchonfeldtLecuona C. Concerns About Pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med 2013; 7:147-149.

Du YT, Roberts AP, Torpy DJ. Seizure induced by sudden cessation of pregabalin in a patient with chronic kidney disease. BMJ Case Rep 2017; bcr-2016-219158.

Hellwig TR, Hammerquist R, Termaat J. Withdrawal symptoms after gabapentin discontinuation. Am J Health Syst Pharm 2010; 67:910-912.

Di Fabio R, D’Agostino C, Baldi G, Pierelli F. Delirium after gabapentin withdrawal. Case report. Can J Neurol Sci 2013; 40:126-127.

Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother 2016; 50:229-233.

Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal gabapentin withdrawal syndrome. Pediatr Neurol 2015; 53:445-447.

Public Health England, NHS England. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. NHS England. 2014 https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/385791/PHENHS_England_pregabalin_and_gabapentin_advice_Dec_2014. pdf. Accessed May 29, 2019.

Parsons G. Guide to the management of gabapentinoid misuse. Prescriber 2018; 29:25-30.

Schifano F, Chiappini S. Pregabalin: a range of misuse‐related unanswered questions. CNS Neurosci Ther 2019; 25:659-660.